BNP Paribas Financial Markets Sells 38,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

BNP Paribas Financial Markets reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 57.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,831 shares of the biopharmaceutical company's stock after selling 38,641 shares during the quarter. BNP Paribas Financial Markets' holdings in Ultragenyx Pharmaceutical were worth $1,602,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. nVerses Capital LLC purchased a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $33,000. UMB Bank n.a. grew its position in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 352 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $56,000. Capital Performance Advisors LLP purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth $107,000. Finally, Quest Partners LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at $119,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.80% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Down 0.1 %

Shares of NASDAQ:RARE traded down $0.06 during midday trading on Monday, reaching $49.32. The company's stock had a trading volume of 779,745 shares, compared to its average volume of 774,903. Ultragenyx Pharmaceutical Inc. has a 12-month low of $37.02 and a 12-month high of $60.37. The firm has a 50 day moving average of $51.17 and a 200-day moving average of $48.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business had revenue of $139.49 million for the quarter, compared to analysts' expectations of $135.28 million. During the same quarter in the prior year, the company earned ($2.23) earnings per share. The business's revenue was up 42.3% compared to the same quarter last year. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RARE. JPMorgan Chase & Co. lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday, November 21st. TD Cowen upped their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. HC Wainwright boosted their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $87.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.